
Applied Molecular Transport AMTI
Quarterly report 2023-Q3
added 11-09-2023
Applied Molecular Transport Interest Expense 2011-2026 | AMTI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -4 K | -124 K | -111 K | -26 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4 K | -124 K | -66.2 K |
Quarterly Interest Expense Applied Molecular Transport
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3 K | -20 K | -13 K | - | -1 K | 2 K | 4 K | - | -6 K | -62 K | -22 K | - | -29 K | -101 K | 49 K | - | -3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49 K | -101 K | -15.8 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Assembly Biosciences
ASMB
|
117 K | $ 28.49 | 0.11 % | $ 319 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 19.61 | 0.59 % | $ 917 M | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 14.72 | 1.59 % | $ 6.11 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
80.6 M | $ 221.08 | -0.36 % | $ 5 B | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.4 | 1.82 % | $ 357 M | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 155.38 | -0.98 % | $ 7.73 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 55.05 | 1.7 % | $ 10.6 B | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.46 | 1.76 % | $ 1.03 B | ||
|
Benitec Biopharma
BNTC
|
-126 K | $ 10.92 | -0.55 % | $ 449 M | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
2.65 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Heron Therapeutics
HRTX
|
1.34 M | $ 0.79 | 2.02 % | $ 132 M | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
444 K | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.13 | 2.15 % | $ 199 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.58 | 3.62 % | $ 185 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.47 | 5.54 % | $ 742 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
52 K | - | -5.98 % | $ 34.1 M |